Encaleret clinical trials
Also written CLTX-305.
How each study uses encaleret is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the encaleret studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Calcilytix Therapeutics, Inc., a BridgeBio company (4) · National Institute of Dental and Craniofacial Research (NIDCR) (1)
Studies
Open first, then newest update. How each study uses encaleret is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic HypoparathyroidismRecruitingPhase 3Calcilytix Therapeutics, Inc., a BridgeBio companyNCT07805356Written as Encaleret
- Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)RecruitingPhase 2/3Calcilytix Therapeutics, Inc., a BridgeBio companyNCT07080385Written as Encaleret
- Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Active, not recruitingPhase 3Calcilytix Therapeutics, Inc., a BridgeBio companyNCT05680818Written as Encaleret
- PTH-independent Effects of EncaleretCompletedPhase 2National Institute of Dental and Craniofacial Research (NIDCR)NCT05735015Written as encaleret
- Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1CompletedPhase 2Calcilytix Therapeutics, Inc., a BridgeBio companyNCT04581629Written as Encaleret
Codes
What other systems call encaleret · ClinicalTrials.gg INT016455
- UNII (FDA) EF8081AQ6GENCALERETConfirmed FDA, Wikidata
- Wikidata Q27277151encaleretConfirmed FDA, Wikidata
- NCI Thesaurus C169946EncaleretOne source FDA
- DrugBank DB18096One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | EF8081AQ6G | ENCALERET | Confirmed FDA, Wikidata |
| Wikidata | Q27277151 | encaleret | Confirmed FDA, Wikidata |
| NCI Thesaurus | C169946 | Encaleret | One source FDA |
| DrugBank | DB18096 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.